Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: Discrepant findings in tissue versus stool

Paul John Limburg, David A. Ahlquist, Jorge A. Gilbert, Jonathan J. Harrington, George G. Klee, Patrick C. Roche

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Colorectal tumor-associated antigens are attractive targets for novel stool-screening assays. MUC1, a glycoprotein antigen, is aberrantly expressed in transformed colorectal mucosa and represents a candidate fecal biomarker. In this study, tissue staining and stool testing were performed to further clarify the discriminant potential of MUC1 in markedly different biologic media. One anti-MUC1 monoclonal antibody (MA5) was used for immunohistochemistry and two commercially available MUC1 assay kits (ELSA-CA 15-3 and Truquant BR) were used for stool detection. On tissue staining, MUC1 expression was strong in 40/40 (100%) adenocarcinomas, moderate in 42/55 (76%) adenomas, faint in 8/28 (29%) juxtatumoral mucosa specimens, and absent in 15/15 (0%) nonadjacent mucosa specimens. Conversely MUC1 levels in stool testing did not differ between colorectal cancer cases (N = 14) and controls (N = 14). Based on these results, MUC1 appears to be a functional tumor biomarker in colorectal tissue but not in stool. Bacterial metabolism within stool may unmask the core antigen of MUC1 and account for this discordance in immunoreactivity.

Original languageEnglish (US)
Pages (from-to)494-499
Number of pages6
JournalDigestive Diseases and Sciences
Volume45
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Mucous Membrane
Antibodies
Colorectal Neoplasms
Staining and Labeling
Antigens
Neoplasms
Neoplasm Antigens
Tumor Biomarkers
Adenoma
Glycoproteins
Adenocarcinoma
Biomarkers
Immunohistochemistry
Monoclonal Antibodies

Keywords

  • Colorectal neoplasms
  • MUC1
  • Mucins
  • Stool tests

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Immunodiscrimination of colorectal neoplasia using MUC1 antibodies : Discrepant findings in tissue versus stool. / Limburg, Paul John; Ahlquist, David A.; Gilbert, Jorge A.; Harrington, Jonathan J.; Klee, George G.; Roche, Patrick C.

In: Digestive Diseases and Sciences, Vol. 45, No. 3, 2000, p. 494-499.

Research output: Contribution to journalArticle

Limburg, Paul John ; Ahlquist, David A. ; Gilbert, Jorge A. ; Harrington, Jonathan J. ; Klee, George G. ; Roche, Patrick C. / Immunodiscrimination of colorectal neoplasia using MUC1 antibodies : Discrepant findings in tissue versus stool. In: Digestive Diseases and Sciences. 2000 ; Vol. 45, No. 3. pp. 494-499.
@article{e838cb7fc5644b26a94f32982edf54df,
title = "Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: Discrepant findings in tissue versus stool",
abstract = "Colorectal tumor-associated antigens are attractive targets for novel stool-screening assays. MUC1, a glycoprotein antigen, is aberrantly expressed in transformed colorectal mucosa and represents a candidate fecal biomarker. In this study, tissue staining and stool testing were performed to further clarify the discriminant potential of MUC1 in markedly different biologic media. One anti-MUC1 monoclonal antibody (MA5) was used for immunohistochemistry and two commercially available MUC1 assay kits (ELSA-CA 15-3 and Truquant BR) were used for stool detection. On tissue staining, MUC1 expression was strong in 40/40 (100{\%}) adenocarcinomas, moderate in 42/55 (76{\%}) adenomas, faint in 8/28 (29{\%}) juxtatumoral mucosa specimens, and absent in 15/15 (0{\%}) nonadjacent mucosa specimens. Conversely MUC1 levels in stool testing did not differ between colorectal cancer cases (N = 14) and controls (N = 14). Based on these results, MUC1 appears to be a functional tumor biomarker in colorectal tissue but not in stool. Bacterial metabolism within stool may unmask the core antigen of MUC1 and account for this discordance in immunoreactivity.",
keywords = "Colorectal neoplasms, MUC1, Mucins, Stool tests",
author = "Limburg, {Paul John} and Ahlquist, {David A.} and Gilbert, {Jorge A.} and Harrington, {Jonathan J.} and Klee, {George G.} and Roche, {Patrick C.}",
year = "2000",
doi = "10.1023/A:1005484921740",
language = "English (US)",
volume = "45",
pages = "494--499",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Immunodiscrimination of colorectal neoplasia using MUC1 antibodies

T2 - Discrepant findings in tissue versus stool

AU - Limburg, Paul John

AU - Ahlquist, David A.

AU - Gilbert, Jorge A.

AU - Harrington, Jonathan J.

AU - Klee, George G.

AU - Roche, Patrick C.

PY - 2000

Y1 - 2000

N2 - Colorectal tumor-associated antigens are attractive targets for novel stool-screening assays. MUC1, a glycoprotein antigen, is aberrantly expressed in transformed colorectal mucosa and represents a candidate fecal biomarker. In this study, tissue staining and stool testing were performed to further clarify the discriminant potential of MUC1 in markedly different biologic media. One anti-MUC1 monoclonal antibody (MA5) was used for immunohistochemistry and two commercially available MUC1 assay kits (ELSA-CA 15-3 and Truquant BR) were used for stool detection. On tissue staining, MUC1 expression was strong in 40/40 (100%) adenocarcinomas, moderate in 42/55 (76%) adenomas, faint in 8/28 (29%) juxtatumoral mucosa specimens, and absent in 15/15 (0%) nonadjacent mucosa specimens. Conversely MUC1 levels in stool testing did not differ between colorectal cancer cases (N = 14) and controls (N = 14). Based on these results, MUC1 appears to be a functional tumor biomarker in colorectal tissue but not in stool. Bacterial metabolism within stool may unmask the core antigen of MUC1 and account for this discordance in immunoreactivity.

AB - Colorectal tumor-associated antigens are attractive targets for novel stool-screening assays. MUC1, a glycoprotein antigen, is aberrantly expressed in transformed colorectal mucosa and represents a candidate fecal biomarker. In this study, tissue staining and stool testing were performed to further clarify the discriminant potential of MUC1 in markedly different biologic media. One anti-MUC1 monoclonal antibody (MA5) was used for immunohistochemistry and two commercially available MUC1 assay kits (ELSA-CA 15-3 and Truquant BR) were used for stool detection. On tissue staining, MUC1 expression was strong in 40/40 (100%) adenocarcinomas, moderate in 42/55 (76%) adenomas, faint in 8/28 (29%) juxtatumoral mucosa specimens, and absent in 15/15 (0%) nonadjacent mucosa specimens. Conversely MUC1 levels in stool testing did not differ between colorectal cancer cases (N = 14) and controls (N = 14). Based on these results, MUC1 appears to be a functional tumor biomarker in colorectal tissue but not in stool. Bacterial metabolism within stool may unmask the core antigen of MUC1 and account for this discordance in immunoreactivity.

KW - Colorectal neoplasms

KW - MUC1

KW - Mucins

KW - Stool tests

UR - http://www.scopus.com/inward/record.url?scp=0034030094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034030094&partnerID=8YFLogxK

U2 - 10.1023/A:1005484921740

DO - 10.1023/A:1005484921740

M3 - Article

C2 - 10749323

AN - SCOPUS:0034030094

VL - 45

SP - 494

EP - 499

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -